Actinomyces on Pap smears

A Pap smear is a microscope screening test for cervical cells, and it can also pick up bacteria, yeast, and other organisms mixed in with those cells. Actinomyces is one of those organisms: a clumped, thread-like bacterium that often turns up in smears from people using an intrauterine device. (pathologyoutlines.com) Pathology references describe Actinomyces species as filamentous, Gram-positive anaerobic bacteria that can live in the female genital tract without causing disease. The International Agency for Research on Cancer’s cervical cytology atlas shows the classic Pap-smear picture as aggregates of pseudofilamentous material in smears from women with an intrauterine device. (pathologyoutlines.com, screening.iarc.fr) That distinction matters because a Pap smear is a screening test, not a culture and not a biopsy. A report of Actinomyces-like organisms can mean colonization on the surface of the cervix, while true pelvic actinomycosis is uncommon and usually presents with symptoms such as pain, discharge, fever, abscess, or a pelvic mass. (pathologyoutlines.com, pathology.co.za) Guidance used in practice does not treat an incidental Actinomyces finding on a Pap smear the same way it treats a precancerous Pap result. ACOG endorses the American Society for Colposcopy and Cervical Pathology’s risk-based system for abnormal cervical screening, while separate clinical references note that asymptomatic patients with Actinomyces-like organisms generally do not need antibiotics or intrauterine device removal solely because of the smear finding. (acog.org, asccp.org, pathadvantage.com) The harder part is when infection, repair, device-related change, and genuine precancer all produce crowded, dark, irregular cells on the same slide. Cervical cytology uses the Bethesda System to sort those patterns into standardized buckets such as high-grade squamous intraepithelial lesion, abbreviated HSIL, for squamous precancer, and adenocarcinoma in situ, or AIS, for gland-forming precancer. (pmc.ncbi.nlm.nih.gov, screening.iarc.fr) Those labels carry different implications. The Bethesda atlas lists HSIL, squamous cell carcinoma, atypical glandular cells, AIS, and adenocarcinoma as separate reporting categories, and the National Cancer Institute notes that actual cervical cancer cells on screening are rare in people screened regularly. (screening.iarc.fr, cancer.gov) AIS adds another layer because it is less common than squamous precancer and can coexist with it. Pathology references describe AIS as an uncommon human papillomavirus-associated precursor of endocervical adenocarcinoma, with at least 50% of cases coexisting with HSIL in some series. (pathologyoutlines.com) Management also diverges once a glandular lesion is suspected. ASCCP says that when AIS is identified on colposcopic biopsy, the next step is a diagnostic excisional procedure if there is no visible mass suggesting invasive cancer, because clinicians need to rule out invasion and define the extent of disease. (asccp.org) HSIL cytology can also trigger aggressive follow-up, but through a different risk pathway. ACOG’s summary of the 2019 ASCCP guidelines says expedited treatment without a preceding biopsy-confirmed high-grade lesion is preferred for some nonpregnant patients 25 or older when the immediate risk of cervical intraepithelial neoplasia grade 3 or worse reaches 60% or more. (acog.org) Published case reports show why cytologists argue over borderline images. Medical literature includes examples of Actinomyces-associated cervical findings that mimicked high-grade disease or cancer, as well as cases in which surface lesions and deeper tumors produced sampling discordance between Pap results, biopsy, and final pathology. (pmc.ncbi.nlm.nih.gov, pmc.ncbi.nlm.nih.gov) So the practical takeaway is narrow and old-fashioned: the slide is one clue, not the whole diagnosis. In cervical cytology, the final call still depends on matching the smear pattern with human papillomavirus results, symptoms, colposcopy, biopsy, and whether the patient has an intrauterine device in place. (asccp.org, pathologyoutlines.com, pmc.ncbi.nlm.nih.gov)